| ID Source | ID |
|---|---|
| PubMed CID | 9912771 |
| CHEMBL ID | 1922235 |
| SCHEMBL ID | 2227024 |
| MeSH ID | M0570561 |
| Synonym |
|---|
| n-[2-hydroxy-6-[(4-methoxybenzoyl)amino]phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide |
| ym150 |
| kf322k101s , |
| ym150 cpd |
| tanexaban [inn] |
| tanexaban |
| n-(2-hydroxy-6-(4-methoxybenzamido)phenyl)-4-(4-methyl-1,4-diazepan-1-yl)benzamide |
| 365462-23-3 |
| darexaban [inn] |
| unii-kf322k101s |
| CHEMBL1922235 , |
| ym-150 |
| bdbm50358252 |
| darexaban |
| darexaban [who-dd] |
| SCHEMBL2227024 |
| n-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide |
| A874332 |
| DB12289 |
| Q5222570 |
| BS-46688 |
| AT18264 |
| n-(3-hydroxy-2-(4-(4-methyl-1,4-diazepan-1-yl)benzamido)phenyl)-4-methoxybenzamide |
| HY-14853 |
| EX-A5673 |
| DTXSID101030146 |
| CS-0003596 |
| AKOS040751402 |
Darexaban (YM150) is a novel oral anticoagulant that directly inhibits factor Xa. Darexaban is a potent direct factor XA (FXa) inhibitor developed for prophylaxis of venous and arterial thromboembolic disease.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Overall, 38 of the 82 enrolled subjects reported a total of 57 treatment-emergent adverse events (TEAEs)." | ( Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Garcia-Hernandez, A; Groenendaal, D; Heeringa, M; Kadokura, T; Kashiwa, M; Mol, R; Onkels, H; Verheggen, F, 2013) | 0.62 |
| "It is concluded that single and multiple doses of darexaban are safe and well tolerated up to 240 mg with predictable PK and PD profiles in both Caucasians and Japanese, and that ethnicity does not affect its PK, PD or tolerability." | ( Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. Garcia-Hernandez, A; Groenendaal, D; Heeringa, M; Kadokura, T; Kashiwa, M; Mol, R; Onkels, H; Verheggen, F, 2013) | 0.88 |
Plasma concentrations of darexaban glucuronide increased with dose. Cmax and AUC increased dose-dependently after both single and repeated doses in Caucasians and Japanese.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The distinctive, potent activity of inhibitor 14i after oral dosing was explained by this unique pharmacokinetic profile and its favorable membrane permeability." | ( Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. Hachiya, S; Hirayama, F; Ishihara, T; Iwatsuki, Y; Kadokura, T; Kawasaki, T; Koga, Y; Koshio, H; Matsumoto, Y; Mori, K; Moritani, Y; Sakamoto, S; Seki, N; Shigenaga, T; Shiraki, R; Sugasawa, K; Tsukamoto, S, 2011) | 0.59 |
| " In addition, we must be aware to have a deliberate evaluation for each result, even pharmacological profiles of each Xa inhibitors with a 12 hour half-life period shows similarity, the difference in twice-daily dosing with once a day, or the difference in severity of patients' atrial fibrillation risk factor each trial contains might affect the results of phase III trials." | ( [Current status and future of anti-Xa inhibitors]. Nagao, T, 2011) | 0.37 |
| " However, there are several limitations to the use of VKAs including delayed onset of action and dosage titration, numerous food and drug interactions and need for regular laboratory monitoring." | ( Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban. Apostolakis, S; Lip, GY, 2012) | 0.62 |
| " Similar amounts of dosed radioactivity were excreted via faeces (51." | ( Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Groenendaal, D; Hashimoto, T; Heeringa, M; Iwatsubo, T; Kihara, Y; Miyashita, A; Onkels, H; Suzuki, K; Usui, T; van Marle, S; Verheggen, F, 2013) | 0.66 |
| "This double-blind, double-dummy, randomised, phase IIb study (NCT00902928) evaluated different dosing regimens of darexaban compared with enoxaparin (randomised 1:1:1:1:1 to 15 mg twice daily [bid], 30 mg once daily [qd], 30 mg bid or 60 mg qd or enoxaparin 40 mg qd) in patients undergoing elective total hip arthroplasty." | ( Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). Agnelli, G; Eriksson, BI; Gallus, AS; Kashiwa, M; Lassen, MR; Prins, MH; Renfurm, RW; Turpie, AG, 2014) | 2.06 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prothrombin | Homo sapiens (human) | Ki | 100.0000 | 0.0000 | 0.7846 | 9.0000 | AID633344 |
| Coagulation factor X | Homo sapiens (human) | IC50 (µMol) | 0.0546 | 0.0003 | 0.5937 | 10.0000 | AID633334 |
| Coagulation factor X | Homo sapiens (human) | Ki | 0.0310 | 0.0000 | 0.4708 | 9.0000 | AID633342 |
| Plasma kallikrein | Homo sapiens (human) | IC50 (µMol) | 0.0546 | 0.0031 | 2.0241 | 10.0000 | AID633334 |
| Trypsin-1 | Homo sapiens (human) | Ki | 100.0000 | 0.0000 | 1.7676 | 8.9000 | AID633343 |
| Trypsin-2 | Homo sapiens (human) | Ki | 100.0000 | 0.0043 | 0.9487 | 3.2900 | AID633343 |
| Trypsin-3 | Homo sapiens (human) | Ki | 100.0000 | 0.0043 | 0.9487 | 3.2900 | AID633343 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID633344 | Inhibition of human thrombin using chromogenic substrate S2238 by dixon plot analysis | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633341 | Anticoagulant activity in human plasma assessed as concentration required to double the clotting time by coagulometric analysis | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633334 | Inhibition of human factor 10A using chromogenic substrate S2222 by fluorometric analysis | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633342 | Inhibition of human factor 10A using chromogenic substrate S2222 by dixon plot analysis | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633347 | Intrinsic clearance in CD1 mouse liver microsomes assessed as compound remaining at 0.2 uM after 30 mins | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633336 | Anticoagulant activity in mouse assessed as prothrombin time at 100 mg/kg, po measured after 0.5 hrs by coagulometric analysis relative to control | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633345 | Inhibition of human plasma kallikrein using chromogenic substrate S2302 by dixon plot analysis | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633335 | Anticoagulant activity in mouse plasma assessed as concentration required to double the clotting time by coagulometric analysis | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633343 | Inhibition of human trypsin using chromogenic substrate S2222 by dixon plot analysis plot | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633346 | Effective permeability of the compound after 2 hrs by PAMPA at pH 6.5 | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| AID633337 | Anticoagulant activity in mouse assessed as prothrombin time at 100 mg/kg, po measured after 2 hrs by coagulometric analysis relative to control | 2011 | Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23 | Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 27 (96.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 9 (32.14%) | 5.53% |
| Reviews | 9 (32.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (35.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 [NCT01118559] | Phase 1 | 24 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Pharmacokinetic Study of YM150 - The Verification ot the Bioequivalence Between YM150 Formulation-A and YM150 Formulation-B - [NCT01125657] | Phase 1 | 44 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Corona [NCT00994292] | Phase 2 | 1,276 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Pharmacokinetic Study of YM150 - A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet- [NCT01125670] | Phase 1 | 24 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| YM150 Long Term Study - Long-term Study in Patients With a History of Venous Thromboembolism [NCT00937820] | Phase 3 | 87 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Multi-center, Open Label Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness [NCT01028950] | Phase 3 | 52 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Enoxaparin [NCT00353678] | Phase 2 | 1,141 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| An Open-label, Randomized, Two-period Crossover Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Pharmacokinetics of Darexaban and Metabolites in Young Healthy Male Subjects [NCT01405989] | Phase 1 | 26 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase I, Open-Label, Randomized 3-Period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Interactions Between YM150 on Naproxen at Steady-State [NCT01409603] | Phase 1 | 26 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Randomized, Open-label, Two-period Crossover Study in Healthy Male Subjects to Evaluate the Pharmacodynamic Effect of Darexaban (YM150) on Acetyl Salicylic Acid (ASA) and of Darexaban on the Combination of ASA and Clopidogrel at Steady State [NCT01409616] | Phase 1 | 100 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| YM150 Phase III Study - An Open-label, Multi-center Study in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities [NCT00937911] | Phase 3 | 101 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Randomized, Open Label Parallel Group Mechanical Prophylaxis Controlled Comparison Study With YM150, a Direct Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery [NCT00942435] | Phase 3 | 156 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| An Open-label, One-sequence Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Pharmacokinetics of YM150 (Darexaban) and Metabolites in Young Healthy Male Subjects [NCT01406002] | Phase 1 | 26 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Randomized, Open Label, Three-way Crossover Study to Evaluate the Pharmacodynamic Interactions Between Darexaban (YM150)/Darexaban Glucuronide (YM-222714) and Acetyl Salicylic Acid (ASA) in Healthy Male Subjects [NCT01424332] | Phase 1 | 24 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Double Blind, Randomized, Two Period Crossover Study To Determine The Effect of Multiple Doses of 120 MG Modified Release Formulation of YM150 on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects [NCT01514812] | Phase 1 | 24 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| YM150 Clinical Pharmacology Study - Repeated Oral Administration to Elderly Subjects [NCT01514825] | Phase 1 | 36 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YM150 in Healthy Caucasian and Japanese Male and Female Subjects [NCT01655056] | Phase 1 | 82 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| An Open Label Study to Evaluate the Pharmacokinetics of YM150 After a Single Oral Dose of C14-labeled YM150 in Healthy Male Subjects [NCT01657981] | Phase 1 | 6 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||